BPC-157 + TB-500 Dosage: Combined Protocol Guide

These two peptides target different phases of tissue repair. Running them together covers both the acute stabilization and long-term remodeling stages.

Think of recovering from a house fire. BPC-157 is the emergency crew: it stops the damage from spreading, stabilizes structures, and gets the water and electricity running again. It upregulates VEGF to restore blood supply and stabilizes nitric oxide for vascular function (Hsieh et al., Sci Rep, 2020). TB-500 is the rebuilding contractor: it brings in new materials, coordinates the workforce, and rebuilds the structure from the foundation. It promotes actin polymerization for cell migration and modulates inflammation to prevent scar tissue formation (Goldstein & Kleinman, Expert Opin Biol Ther, 2012).

Running both simultaneously means the emergency repair and structural rebuilding happen in parallel rather than sequentially. The non-overlapping mechanisms provide a logical basis for the combination, even though no controlled study has tested BPC-157 and TB-500 together.

Three dosing tiers accommodate different injury severities and user experience levels. All protocols assume subcutaneous injection.

Many vendors sell pre-blended vials containing both BPC-157 and TB-500 in a single lyophilized powder. The most common blend is 10 mg total (5 mg BPC-157 + 5 mg TB-500 or other ratios). Reconstituting a blend vial requires careful math because each injection delivers both peptides in a fixed ratio.

Example: 10 mg blend vial (5 mg BPC-157 + 5 mg TB-500)

Add 2 mL of bacteriostatic water. The resulting concentration: - BPC-157: 5,000 mcg / 2 mL = 2,500 mcg/mL - TB-500: 5,000 mcg / 2 mL = 2,500 mcg/mL

To inject 250 mcg BPC-157 + 250 mcg TB-500, draw 10 units (0.1 mL) on an insulin syringe.

The problem: this fixed ratio delivers equal doses of both peptides, but the standard protocol calls for roughly 5x more TB-500 (2,500 mcg) than BPC-157 (500 mcg). A blend vial with a 1:1 ratio forces you to either underdose TB-500 or massively overdose BPC-157.

Recommendation: if using a blend vial, choose one with a 1:5 ratio (BPC-157:TB-500) to match standard dosing protocols. Alternatively, buy separate vials for full dose flexibility. For reconstitution guidance, use our peptide reconstitution calculator and see our how to reconstitute peptides guide.

Oral BPC-157 + TB-500 capsules bypass the reconstitution complexity but introduce bioavailability considerations. For a full analysis of capsule efficacy, see our BPC-157 + TB-500 capsules guide.

Oral doses are higher than injectable doses to compensate for lower bioavailability. BPC-157 acetate capsules deliver approximately 3% systemically; the gut receives the full local dose. TB-500 oral bioavailability is unproven.

Timing: take capsules with a small meal in the morning. If using 2 capsules daily, space them 6-8 hours apart. Avoid dosing after 2 PM to prevent sleep disruption from BPC-157's dopaminergic effects.

Hybrid approach (oral + injectable): take oral BPC-157 capsules in the morning for GI support and baseline systemic levels. Inject TB-500 subcutaneously near the injury site in the evening for confirmed systemic delivery. This approach gives each peptide its most effective route.

Heavier individuals distribute peptides across a larger volume of tissue and blood. These adjustments scale the standard protocol by body weight.

These weight-based adjustments are extrapolated from body surface area scaling used in pharmacology. No BPC-157 or TB-500 study has conducted formal weight-based dosing analysis in humans. The adjustments represent community consensus, not clinical evidence.

For weight-specific BPC-157 guidance, see our BPC-157 dosage for 200lb male guide. The BPC-157 dosage calculator accounts for body weight automatically.

The nature of the injury determines which peptide to emphasize and where to inject.

Tendon injuries respond well to BPC-157 because it upregulates growth hormone receptor expression in tendon fibroblasts (Chang et al., J Mol Histol, 2011). TB-500 supports the broader remodeling phase. Injecting BPC-157 near the tendon puts the peptide where fibroblast activation matters most.

GI conditions call for oral BPC-157 as the primary agent. Sikiric et al. demonstrated oral BPC-157 heals gastric ulcers and counteracts NSAID-induced GI damage in rats (Sikiric et al., Curr Pharm Des, 2011). TB-500 is optional for GI protocols; if included, inject subcutaneously for reliable systemic delivery.

Muscle injuries benefit from TB-500's actin polymerization effects, which promote satellite cell migration into the damaged fibers. Use the higher end of TB-500 dosing (2.5 mg/day during loading) for significant muscle tears.

Running BPC-157 and TB-500 together follows the same cycling principles as individual peptide protocols, with one addition: the TB-500 taper should begin before the BPC-157 taper.

Standard 8-week cycle structure:

Why taper TB-500 first? TB-500 has a longer biological half-life and accumulates in tissue over the 6-week active phase. Stopping abruptly creates a sharper drop. Tapering over week 7 smooths the transition. BPC-157 has shorter-acting effects and can be tapered quickly in week 8.

Repeat cycles: wait a minimum of 2 weeks (preferably 4) before starting another cycle. This washout allows peptide receptor sensitivity to normalize. Running back-to-back cycles without a break may produce diminishing returns as receptors downregulate.

Extended protocols: some users run 12-week cycles for severe chronic injuries. No safety data covers oral or injectable BPC-157 + TB-500 use beyond 8 weeks. If extending beyond the standard cycle, consult a physician and monitor for unusual symptoms.

Mistake 1: Using a 1:1 dose ratio for BPC-157 and TB-500. A user injects 500 mcg of each peptide daily. Standard protocols call for roughly 5x more TB-500 than BPC-157 by weight (2,500 mcg TB-500 vs 500 mcg BPC-157). At 1:1 dosing, TB-500 is severely underdosed. The fix: follow the standard ratio of 250-500 mcg BPC-157 to 2,000-2,500 mcg TB-500.

Mistake 2: Injecting TB-500 at the injury site when it works systemically. A user injects TB-500 directly into a sore knee, getting only local concentration when the peptide distributes systemically regardless of injection location. BPC-157 benefits from local injection; TB-500 does not. The fix: inject TB-500 in the abdomen or thigh for easy access and rotate sites. Direct BPC-157 near the injury.

Mistake 3: Using the same reconstitution volume for separate vials of different sizes. A user adds 2 mL of bacteriostatic water to both a 5 mg BPC-157 vial and a 5 mg TB-500 vial, then draws 10 units from each (250 mcg BPC-157, 250 mcg TB-500). They are underdosing TB-500 by 10x. The fix: calculate each vial's concentration separately and draw the correct volume for each target dose. Use the peptide reconstitution calculator.

Mistake 4: Skipping the loading phase and starting at maintenance doses. A user injects 250 mcg BPC-157 and 1.5 mg TB-500 twice weekly from day one. Tissue saturation takes longer at these reduced doses, delaying the onset of noticeable effects by 2-3 weeks. The fix: run 2 weeks at full daily dosing before stepping down to maintenance frequency.

No human clinical trial has tested BPC-157 and TB-500 in combination. All dosing protocols are derived from individual peptide animal research, pharmacological extrapolation, and community reports.

BPC-157 safety profile: no lethal dose identified in animal studies. No organ toxicity, mutagenicity, or reproductive toxicity in preclinical testing (Sikiric et al., Gut Liver, 2020). The 2025 human IV pilot (20 mg single dose) reported no adverse events (Altern Ther Health Med, 2025).

TB-500 safety profile: Thymosin Beta-4 was tested in Phase I/II human trials for chronic wounds (injection) and dry eye (topical). Pickering & Mazur (2025) reviewed TB-500 use in sports medicine and found a favorable safety profile with no serious adverse events in clinical settings.

Angiogenesis caution: both BPC-157 and TB-500 promote new blood vessel formation. Users with a history of cancer or active tumors should avoid this stack. The theoretical risk of feeding blood supply to tumors exists with any angiogenesis-promoting protocol. Consult an oncologist before using either peptide if cancer history is present.

Anticoagulant interactions: both peptides may affect platelet function and wound healing pathways. Users on warfarin, heparin, or direct oral anticoagulants should inform their physician before starting the stack.

Neither peptide is FDA-approved for human use. BPC-157 is classified as a category 2 risk compound for injectable forms. These protocols do not constitute medical advice.